FindTrial
Sign In

Liquid biopsy in metastatic brain tumours

Paired exosomal mRNA, tumoral somatic DNA sequencing and DNA methylation profiling in patients with primary and / or metastatic brain tumors on radiology, to develop a liquid biopsy test. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/071572
Enrollment
1000
Registered
2024-07-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-D49- Neoplasms

Interventions

Control Intervention1: Nil: Nil

Sponsors

Exsegen Genomics Research Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects with suspected primary or secondary brain tumor on neuroimaging 2. Age-any age with proper consent/assent 3. Provision of signed and dated informed consent form; by patient or guardian/parent 4. Stated willingness to comply with all study procedures

Exclusion criteria

Exclusion criteria: Patients who fail to meet all of the above criteria for cases will be excluded.

Design outcomes

Primary

MeasureTime frame
Ability to distinguish between a secondary malignant neoplasm and a non-malignant condition using a liquid biopsy test, with an accuracy approaching the traditional biopsy.Timepoint: Baseline, 12 weeks, 26 weeks and 52 weeks—

Secondary

MeasureTime frame
1. Ability to distinguish between the secondary neoplasm & other primary malignant neoplasms of the brain. 2. Ability to diagnose the possible site of the primary neoplasm from which the secondary malignant brain neoplasm has arisen.Timepoint: Baseline, 12 weeks, 26 weeks & 52 weeks—

Countries

India

Contacts

Public ContactDr Amitava Ray MBBS MD FRCSEd FRCS Neurosurgery

EXSEGEN GENOMICS RESEARCH PRIVATE LIMITED

amit@exsegen.com9000420030

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026